Page 2 - Michael Irwig News Today

Many states have enacted or contemplated limits or outright bans on transgender medical treatment, with conservative U.S. lawmakers saying they are worried about young people later regretting irreversible body-altering treatment.

In updated treatment guidelines issued last year, the World Professional Association for Transgender Health said evidence of later transition regret is scant, but that patients should be told about the possibility during psychological counseling.

How many youth change their appearances with hormones or surgery only to later change their minds and detransition?

Across the United States, thousands of youths are lining up for gender-affirming care. But when families decide to take the medical route, they must make decisions about life-altering treatments that have little scientific evidence of their long-term safety and efficacy.

By JACQUELINE MITCHELL | Beth Israel Deaconess April 20, 2021Research LightFieldStudios/iStock / Getty Images Plus Transgender people have a higher burden of cardiovascular disease and high blood pressure than cisgender people. Although doctors have prescribed gender-affirming hormone therapy to transgender men and transgender women for more than 25 years, little is known about how this treatment may impact rates of high blood pressure in this patient population or how the effec...

Hormone treatments may raise blood pressure in transgender people By (0) Gender-affirming hormone therapy was linked to changes in systolic blood pressure, a new study found. Photo by agilemktg1/Flickr Photo by agilemktg1/Flickr Monitoring blood pressure is important for transgender people, according to new research, which found changes in systolic blood pressure after the start of gender-affirming hormone therapy. Transgender men and transgender women have a higher burden of heart attack, st...

Merck decided not to warn consumers of those potential risks in a 2011 update of the popular drug's label.

February 04, 2021 published at 6:20 AMReuters A bottle of Propecia is seen on a pharmacy shelf in New York City, US, August 8, 2019. Reuters Newly unsealed court documents and other records show that Merck & Co and US regulators knew about reports of suicidal behavior in men taking the company’s anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug’s label. Internal records from Merck were made public in late ...

12 Min Read (Reuters) - Newly unsealed court documents and other records show that Merck & Co and U.S. regulators knew about reports of suicidal behavior in men taking the company’s anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug’s label. FILE PHOTO: A bottle of Propecia is seen on a pharmacy shelf in New York City, U.S., August 8, 2019. REUTERS/Zachary Goelman Internal records from Merck were made public...